Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-07 |
2024-09 |
-1.84 |
N/A |
N/A |
N/A |
2024-08-01 |
2024-06 |
-3.47 |
-3.33 |
0.14 |
4.03% |
2024-05-02 |
2024-03 |
-3.59 |
N/A |
N/A |
N/A |
2024-05-02 |
2024-03 |
-3.59 |
-3.07 |
0.52 |
14.48% |
2024-02-22 |
2023-12 |
-0.78 |
N/A |
N/A |
N/A |
2024-02-22 |
2023-12 |
-0.78 |
0.55 |
1.33 |
170.51% |
Date |
Firm |
Action |
From |
To |
2023-09-12 |
Argus Research |
Upgrade |
Buy |
Buy |
2023-08-03 |
TD Cowen |
Downgrade |
Outperform |
Market Perform |
2023-08-03 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-03 |
B of A Securities |
Upgrade |
Neutral |
Neutral |
2023-08-03 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-08-02 |
Deutsche Bank |
Downgrade |
Buy |
Hold |
Date |
Name |
Relation |
Quantity |
Description |
2024-07-30 |
AFEYAN NOUBAR BOGHOS |
Director |
6.86M |
Sale |
2022-12-27 |
ANDRES JUAN |
Chief Technology Officer |
12.80K |
Sale |
2024-02-15 |
BANCEL STEPHANE J |
Chief Executive Officer |
21.08M |
Sale |
2024-05-02 |
BERENSON STEPHEN A. |
Director |
22.20K |
Conversion of Exercise of derivative security |
2023-12-05 |
GARAY ARPA |
Officer |
3.69K |
Sale |
2024-09-02 |
HOGE STEPHEN |
President |
1.60M |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Baillie Gifford and Company |
45.71M |
5.55B |
12.01% |
2023-06-29 |
Vanguard Group Inc |
27.46M |
3.34B |
7.22% |
2023-06-29 |
Blackrock Inc. |
24.16M |
2.94B |
6.35% |
2023-06-29 |
State Street Corporation |
14.23M |
1.73B |
3.74% |
2023-06-29 |
Flagship Pioneering Inc. |
12.89M |
1.57B |
3.39% |
2023-06-29 |
Coatue Management LLC |
6.55M |
795.35M |
1.72% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
10.11M |
1.23B |
2.66% |
2023-05-30 |
Vanguard International Growth Fund |
9.42M |
1.20B |
2.47% |
2023-06-29 |
Vanguard 500 Index Fund |
7.81M |
948.38M |
2.05% |
2023-08-30 |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF |
6.46M |
730.48M |
1.70% |
2023-07-30 |
Vanguard Specialized-Health Care Fund |
4.45M |
523.90M |
1.17% |
2023-05-30 |
Fidelity 500 Index Fund |
3.70M |
472.16M |
0.97% |
Split |
Date |
1 : 10 |
2017-08-03 |